UNSPSC 51191962: Thiamine triphosphorate

This classification denotes a b vitamin with the molecular formula C12H19N4O10P3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 464M6AQ7IV, chemically known as thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-4-methyl-5-(4,6,8,8-tetrahydroxy-3,5,7-trioxa-4,6,8-triphosphaoct-1-yl)-, inner salt, p,p',p''-trioxide, but more generally known as thiamine triphosphorate, which bears US NIH Compound Identifier 18989.

European Medicines Agency schedules thiamine triphosphorate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10969MIG. Most nations, for tariff purposes, schedule thiamine triphosphorate under HS 29362200. SMILES: CC1C(SC[N+]1CC2CNC(NC2N)C)CCOP(=O)([O-])OP(=O)(O)OP(=O)(O)O.

UNSPSC 51191962 Thiamine triphosphorate, a Commodity code, covers chemical and pharmaceutical products acquired by state and local health, water, and human services agencies for clinical, operational, and treatment purposes. The recent solicitations tagged under this code reflect a broader pattern of municipal and multi-state procurement of pharmaceutical and chemical supplies — sodium bisulfite for water treatment operations and generic pharmaceuticals and OTC products for distribution across participating state and local facilities. The City of Meriden and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the issuing-body types active under this code: municipalities procuring single-commodity chemicals for utilities, and state cooperative purchasing vehicles establishing multi-vendor contracts to serve multiple jurisdictions and member agencies across regions.

Activity under this code spans Connecticut and Minnesota with multi-state reach through MMCAP's participation model, which includes Oregon and other member states. Representative recent solicitations include the City of Meriden's IFB for sodium bisulfite chemical supply (solicitation B02715, due July 29, 2026) for its Water Pollution Control Facility, evaluated on unit-cost basis with standard bonding and insurance requirements; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (solicitation S1070000015802, due March 26, 2026), which establishes contracts for distribution through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing terms, and 5 percent each on administrative fee compliance, EDI capability, and cGMP/DSCSA certification. Award under MMCAP occurs through May 15, 2026, with contracts effective July 1, 2026.